Security readout for executives and security teams
Plain-English summary
CVE-2021-45094 reports cross-site scripting in Imprivata Privileged Access Management, formerly Xton Privileged Access Management, version 2.3.202112051108. The public record does not provide severity, CVSS, exploit details, or a named fixed version.
Executive priority
Prioritize verification if this PAM product is deployed. The business risk could be material because PAM systems protect privileged access, but urgency cannot be rated confidently from the public record alone.
Technical view
The CVE description states that Imprivata Privileged Access Management 2.3.202112051108 allows XSS. Structured affected-product data is incomplete, and no CWE, CVSS vector, vulnerable endpoint, authentication condition, or remediation release is provided in the supplied sources.
Likely exposure
Exposure is likely limited to organizations running the named PAM product and version. Because the CVE affected-product fields are listed as n/a, teams should verify product lineage and installed build numbers against Imprivata records.
Exploitation context
The source bundle does not cite active exploitation, public exploit code, or CISA KEV listing. XSS in a PAM interface can still matter because admin sessions and privileged workflows may be high-value targets.
Researcher notes
Public evidence is sparse. The CVE record names XSS but omits endpoint, attack preconditions, privilege requirements, impact scope, and fix information. Avoid assuming exploitability beyond the stated product/version until vendor or advisory details are confirmed.
Mitigation direction
- Inventory Imprivata/Xton PAM deployments and installed versions.
- Check Imprivata guidance for fixed releases or supported upgrade paths.
- Limit PAM web interface access to trusted administrative networks.
- Apply vendor updates if a fixed release is confirmed.
- Review session, MFA, and administrative access controls for PAM users.
Validation and detection
- Confirm whether version 2.3.202112051108 exists in your environment.
- Review vendor advisories or support cases for CVE-2021-45094.
- Check PAM web logs for unusual administrative UI activity.
- Run only approved, non-destructive validation in a test environment.
- Document any compensating controls around PAM interface access.
Public sources used
Generated from the cited source records. This long-tail analysis has not been individually reviewed by a named human.
Conservative CVE-to-ATT&CK context
These mappings and lookup hints may be relevant to the vulnerability behavior, CWE, affected product, or exposure path. Glexia-inferred context is not an official MITRE, ATT&CK, CWE, or CVE Program mapping.
ATT&CK lookup starting points
Use these exact CWE pages and searches to review the Glexia ATT&CK library from this CVE's weakness and description context.
CVE-2021-45094 mapping review
Open the CVE-to-ATT&CK bridge for reviewed, inferred, or future official mappings tied to this CVE.
Open ATT&CK lookup- Severity
- Unknown
- CVSS
- Not scored
- Known Exploited
- No
- Published
CNA and ADP enrichment extracted from CVE v5
These fields come from the CVE record and ADP containers, not from Glexia's Take. They preserve time-varying source decisions such as CISA SSVC, KEV status, CVSS metrics, and provider references.
CVSS and timeline data
No CVSS vectors or timeline events were available in the normalized CVE source material.
Source materials
- CVE List V5 sourceCVE List V5
- https://www.imprivata.com/privileged-access-managementCVE reference
- https://aegis9.com.au/blog/CVE reference
- https://www.aegis9.com.au/blog/5/CVE reference
Products and packages named in the record
CWE details
CWE links open Glexia weakness intelligence pages with official CWE context, developer remediation guidance, and related CVE mappings.